Treatment of Candida infection: a view from the trenches!
- 1 December 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 18 (6) , 490-495
- https://doi.org/10.1097/01.qco.0000191516.43792.61
Abstract
To provide an overview of the treatment of Candida infections from the perspective of the infectious disease clinician in the community. An insight is given into relevant issues as they apply to clinical practice. As community hospitals strive to provide state-of-the-art medical care to critically ill patients, effective infection control programs and the infectious disease consultation availability become indispensable. Candida infections rank as the fourth most common cause of nosocomial bloodstream infections. Although C. albicans remains the most common pathogen, emerging trends in invasive candidiasis are notable for a dramatic increase in infections due to non-albicans Candida species, reflecting changes in clinical practice. These trends affect our practice because infections with non-albicans species raise concerns for inherent decreased antifungal susceptibility, ultimately impacting our preventive, empirical and therapeutic approaches. It seems inevitable for most acutely ill patients today to be admitted to the intensive care unit, thus increasing their risk for nosocomial infections. In addition, cost containment efforts may force patients receiving intravenous therapy into less supervised environments, potentially increasing their risk for candidemia. Potentially fatal Candida infections are commonplace in seriously ill hospitalized patients. The infectious disease physician is challenged to develop expertise in using the newly introduced antifungal agents, applying evidence-based guidelines developed from quality randomized clinical trials. The infectious disease specialist is called to play a multidisciplinary role formulating infection control policies, developing drug formularies, educating the staff and treating the sickest patients. Infection surveillance in local communities coupled with available antifungal agents may improve our management of Candida infections.Keywords
This publication has 17 references indexed in Scilit:
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Epidemiology of Candidemia: 3-Year Results from the Emerging Infections and the Epidemiology of Iowa Organisms StudyJournal of Clinical Microbiology, 2002
- Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000Journal of Clinical Microbiology, 2002
- International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance ProgramJournal of Clinical Microbiology, 2001
- Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997Clinical Infectious Diseases, 2001
- Changing spectrum of invasive candidiasis and its therapeutic implicationsClinical Microbiology & Infection, 2001
- Candidemia Before and During the Fluconazole Era: Prevalence, Type of Species and Approach to Treatment in a Tertiary Care Community HospitalScandinavian Journal of Infectious Diseases, 2001
- Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998Antimicrobial Agents and Chemotherapy, 2000
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- National Surveillance of Nosocomial Blood Stream Infection Due to Species of Candida Other than Candida albicans: Frequency of Occurrence and Antifungal Susceptibility in the SCOPE ProgramDiagnostic Microbiology and Infectious Disease, 1998